⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ST Pharm Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ST Pharm Co., Ltd.
↗Siheung, South Korea
ST Pharm is a South Korean contract development and manufacturing organization (CDMO) specializing in the production of active pharmaceutical ingredients (APIs), with a strong focus on oligonucleotide therapeutics, mRNA, and small molecule APIs. Established in 1983 (formerly Samchully Pharmaceutical), the company has evolved into a global leader in nucleic acid therapeutic manufacturing, providing end-to-end services from process development to commercial-scale cGMP production.
The company is recognized for its proprietary technologies, including the SmartCap® mRNA platform and advanced oligonucleotide synthesis capabilities. ST Pharm operates multiple cGMP-certified facilities and serves a global client base, including major pharmaceutical and biotechnology firms, by leveraging its expertise in complex chemical synthesis, impurity management, and regulatory compliance.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$200M-$300M
Founded:1983
Ownership:public
Status:operating
STOCK
Exchange:KRX
Ticker:237690
Market Cap:$1.89B
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule, Oligonucleotide, mRNA, Lipid Nanoparticles (LNP)
Active Trials:2
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Dong-A Socio Holdings
Subsidiaries:AnaPath Research & Service
Key Partnerships:Evonik (RNA and nucleic acid delivery), Global pharmaceutical companies (various undisclosed API supply contracts)
COMPETITION
Position:Leader
Competitors:Agilent Technologies, Nitto Avecia, WuXi TIDES, Bachem
LINKS
Website:stpharm.co.kr
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ST Pharm Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.